Page 7 - மருந்துகள் பாலிஸீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Richard Leonard refuses role on Scottish Labour front bench as Sarwar announces new team
thenational.scot - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenational.scot Daily Mail and Mail on Sunday newspapers.
Anas Sarwar announces Campaign Cabinet as he eyes progress at next Holyrood election
dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.
Last modified on Sat 27 Feb 2021 14.52 EST
Proposals for prisons to trial a free scheme providing cannabis to inmates to ascertain whether it reduces violence, overdose deaths and addiction to stronger drugs have been backed by the UK government’s former chief drug adviser.
Prof David Nutt, from Imperial College London, said he was fully supportive of the idea and that he was considering a study on reducing prisoners’ drug dependence with cannabis in an ongoing trial.
“The idea of drug testing in prisons was not at all thought through when it was introduced in 1996,” said Nutt, chair of DrugScience, which advocates for evidence-based drug policy.
Shares of eight pharmaceutical companies rose by 0.5% to 3.4% after the cabinet approved Production Linked Incentive (PLI) scheme for pharmaceuticals segment.Hikal (up 3.46%), Neuland Laboratories (up 3.08%), IPCA Laboratories (up 2.85%), Alkem Laboratories (up 1.43%), Torrent Pharmaceutical (up 1.09%), Biocon (up 0.6%), Cadila Healthcare (up 0.58%) and Aurobindo Pharma (up 0.52%) were top gainers in pharmaceutical space.
The Union Cabinet on Wednesday approved Production Linked Incentive (PLI) scheme for pharmaceuticals over a period of Financial Year 2020-21 to 2028-29.
The scheme will benefit domestic manufacturers, help in creating employment and is expected to contribute to the availability of wider range of affordable medicines for consumers. The scheme is also expected to bring in investment of Rs 15,000 crore in the pharmaceutical sector.
The drug major announced the launch of capecitabine tablets, a therapeutic equivalent generic version of Xeloda tablets, approved by the U.S. Food and Drug Administration (USFDA).
Capecitabine is an anti-cancer ( antineoplastic or cytotoxic ) chemotherapy drug. Dr. Reddy s capecitabine tablets, USP are available in 150mg and 500mg strengths in bottle count sizes of60 and 120, respectively.
The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.
Dr. Reddy s Laboratories is an integrated pharmaceutical company. The scrip fell 1.79% to Rs 4612, extending decline for fourth day. The stock has declined by 4.4% in four sessions.
vimarsana © 2020. All Rights Reserved.